If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-02. Numbers and descriptions here follow the published literature rather than marketing material.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
A band mask is a heavy duty full-face mask with many of the characteristics of a lightweight demand helmet. In structure it is the front section of a lightweight helmet from above the faceplate to below the demand valve and exhaust ports, including the bailout block and communications connections on the sides. This rigid frame is attached to a neoprene hood by a metal clamping band, hence the name. It is provided with a padded sealing surface around the frame edge which is held firmly against the diver's face by a rubber "spider", a multiple strap arrangement with a pad behind the diver's head, and usually five straps which hook onto pins on the band. The straps have several holes so the tension can be adjusted to get a comfortable seal. A band mask is heavier than other full face masks, but lighter than a helmet, and can be donned more quickly than a helmet. They are often used by the standby diver for this reason.
=== Administrative history === Wilmslow was an ancient parish in the Macclesfield Hundred of Cheshire. The parish was subdivided into four townships, called Bollin Fee, Chorley, Fulshaw, and Pownall Fee. The town centre and the parish church of St Bartholomew's lay in the Bollin Fee township. From the 17th century onwards, parishes were gradually given various civil functions under the poor laws, in addition to their original ecclesiastical functions. In some cases, including Wilmslow, the civil functions were exercised by each township separately rather than the parish as a whole. In 1866, the legal definition of 'parish' was changed to be the areas used for administering the poor laws, and so the townships each became separate civil parishes, which therefore diverged from the ecclesiastical parish. In 1862, a Chorley local government district was created, governed by an elected local board. The district covered the eastern part of the Chorley township, plus small adjoining parts of the Bollin Fee and Fulshaw townships. The Chorley district was renamed Alderley Edge in 1894. In 1878, a separate Wilmslow local government district was created covering the remainder of Bollin Fee and Fulshaw, plus Pownall Fee apart from the area north of the River Bollin and River Dean; the excluded area north of the rivers contained the hamlet of Styal. Local government districts were reconstituted as urban districts under the Local Government Act 1894.
== Television episodes == "Half-Life", Icons season 3, episode 17 (2004) "Half-Life", Odyssey 5 episode 17 (2002) "Half Life", La Femme Nikita season 2, episode 7 (1998) "Half Life", Logan's Run episode 6 (1977) "Half Life", Medical Investigation episode 17 (2005) "Half Life", New Tricks series 8, episode 9 (2011) "Half Life", Sea Patrol season 3, episode 7 (2009) "Half Life", SeaChange season 3, episode 13 (2000)
Sources: en.wikipedia.org
Acute and chronic exposure also reduces glutathione reductase, an enzyme that catalyzes the reduction of glutathione disulfide (GSSG) to the sulfhydryl form glutathione (GSH), which is a critical molecule in resisting oxidative stress and maintaining the reducing environment of the cell.
During the opening remarks of the talks, Xi said that "the whole world is watching our meeting. Currently, a transformation not seen in a century is accelerating across the globe, and the international situation is fluid and turbulent". He asked whether China and the US could escape the Thucydides trap and create a "new paradigm of relations". He congratulated the US on its 250th anniversary and added that China and the US "should be partners not rivals". He said that China and the US had agreed to establish a constructive China–US relationship of strategic stability, which he said included "benign stability with competition kept within bounds, a normalized stability in which differences are kept manageable, and an enduring stability in which peace can be expected". Xi said "the Taiwan question is the most important issue in China–US relations", adding "If it is handled properly, the bilateral relationship will enjoy overall stability. Otherwise, the two countries will have clashes and even conflicts, putting the entire relationship in great jeopardy". Xi said "'Taiwan independence' and cross-Strait peace are as irreconcilable as fire and water" while adding that peace in the Taiwan Strait is the "greatest common ground between China and the United States". Trump told Xi, "You're a great leader, sometimes people don't like me saying it, but I say it anyway". He said some people called this "the biggest summit ever" and that he looks forward "very much" to the discussions.
== Further reading == Calmes, M.; Daunis, J. (1999). "How to build optically active α-amino acids". Amino Acids. 16 (3–4): 215–250. doi:10.1007/BF01388170. PMID 10399014. S2CID 36591079. Han, Y.; Lin, J.; Liao, S.; Qiu, W.; Cai, C.; Hruby, V.J. (2002). "Stereoselective synthesis of highly topographically constrained β-isopropyl substituted aromatic amino acids". In Tam, J.P.; Kaumaya, P.T.P. (eds.). Peptides Frontiers of Peptide Science. American Peptide Symposia. Vol. 5. Springer. pp. 241–243. doi:10.1007/0-306-46862-X_98. ISBN 0-7923-5160-6.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.